Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy

Vaccination with dendritic cells (DCs), the most potent professional antigen-presenting cells in the body, is a promising approach in cancer immunotherapy. However, tumors induce immunosuppression in their microenvironment that suppresses and impairs the function of DCs. Therefore, human clinical tr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Zafar, Sadia, Parviainen, Suvi, Siurala, Mikko, Hemminki, Otto, Havunen, Riikka, Tähtinen, Siri, Bramante, Simona, Vassilev, Lotta, Wang, Hongjie, Lieber, Andre, Hemmi, Silvio, de Gruijl, Tanja, Kanerva, Anna, Hemminki, Akseli
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5353943/
https://ncbi.nlm.nih.gov/pubmed/28344872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1265717
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars